LONDON, July 18 /PRNewswire/ -- The significance of nucleic acid and its multiple applications in a large number of research fields has increased the demand for pure isolations in Europe. Since nucleic acid is the fundamental substance preceding all other procedures in drug research, its integrity can enhance or damage research quality'
Frost & Sullivan (www.healthcare.frost.com) finds that Genomics Markets/Nucleic Acid Isolation Markets in Europe earned revenues of $670.0 million in 2005 and estimates this to reach $1490.2 million in 2012.
Integration of automation and robotics in the isolation of nucleic acid also plays a critical role in meeting demand for purity. Further technological value addition will only boost the instrumentation revenues in the market.
In this environment, automation has become instrumental in optimizing sample preparation stages - especially for low- and medium-throughput operations. Suppliers of automation equipment to research institutions and pharmaceutical companies constantly try to meet customers' demand for an open platform technology base with reagents and consumables.
"Automation vendors are working toward knowing their customers' needs, and customizing their solutions to ensure maximum satisfaction," says Frost & Sullivan Research Analyst Charanya Ramachandran.
The market is very dynamic as brand barriers and customer loyalty pose problems for new participants. There is tremendous competition within the DNA as well as the RNA segments, which challenges an entrant to the market.
Most end users in this market give importance to reliability in their instrumentation suppliers, and hence, brand loyalty is very high. Vendors with sufficient visibility and a proven market record, especially in the case of reagents and purification kits that produce nucleic acid molecules with maximum purity, are able to make profits.
The best strategy for a niche participant would be to form a strategic alliance with a larger brand to gain better visibility. In addition, suppliers could offer a complete optimal cost solutions base using innovative technology, since the demand for stand-alone purification instrumentation is not very high.
"Some factors which can enhance a company's position within the market include forming strategic alliances or exclusive licensing agreements with a major innovative technology vendor," notes Ramachandran.
Responsive service, reliable accuracy and quality, as well as attractive customer schemes could garner customer loyalty over time. Established suppliers could maintain and increase their base by building on customer loyalties through loyalty programs and a combination of selling and pricing strategies.
Genomics Markets/Nucleic Acid Isolation Markets in Europe is part of the Drug Discovery Technologies subscription, which also includes research in the following markets: Opportunities for Proteomics technologies in Europe and Opportunities for Laboratory Information Management Systems in Eastern Europe. All research services included in subscriptions provide detailed market opportunities and industry trends evaluated following extensive interviews with market participants. Interviews are available to the press.
If you are interested in a virtual brochure, which provides manufacturers, end users, and other industry participants with an overview of the latest analysis of the nucleic acid isolation markets in Europe (H055-55) then send an e-mail to Radhika Menon Theodore, at rmtheodore@frost.com with your full name, company name, title, telephone number, e-mail address, city, state, and country. We will send you the overview by e-mail upon receipt of the above information.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com.
Nucleic Acid Isolation Markets in Europe H055-55 Contact: Radhika Menon Theodore Corporate Communications - Europe P: +91-44-42044541 F: +91-44-24314264 E: rmtheodore@frost.com Melina Trevino Corporate Communications - Americas P: +1-210-247-2440 F: +1-210-348-1003 E: melina.trevino@frost.com Surbhi Dedhia Corporate Communications - India P: +91-22-5001-3431 E: sdedhia@frost.com Jasminder Kaur Corporate Communications - Asia Pacific P: +65-68900937 E: jkaur@frost.com Sharmin Jassal Corporate Communications - Australia P: +61-2-8247-8900 F: +61-2-9252-8066 E: sjassal@frost.comwww.frost.com
Keywords in this release: genomics markets, nucleic acid isolation, Europe, drug research, instrumentation, research, automation, open platform, technology base, reagents, consumables, DNA, RNA segments, market, trends, technology, service, forecast, market share
Frost & SullivanCONTACT: Contact: Radhika Menon Theodore, Corporate Communications -Europe, P: +91-44-42044541, F: +91-44-24314264, E: rmtheodore@frost.com,Melina Trevino, Corporate Communications - Americas, P: +1-210-247-2440, F:+1-210-348-1003, E: melina.trevino@frost.com, Surbhi Dedhia, CorporateCommunications - India, P: +91-22-5001-3431, E: sdedhia@frost.com,Jasminder Kaur, Corporate Communications - Asia Pacific, P: +65-68900937,E: jkaur@frost.com, Sharmin Jassal, Corporate Communications - Australia,P: +61-2-8247-8900, F: +61-2-9252-8066, E: sjassal@frost.com
